Cancer Immunity (5 June 2009) Vol. 9, p. 5

Cancer Immunity (9 October 2009) Vol. 9, p. 9

Tumor antigens are the primary target of therapeutic cancer vaccines. We set out to define and compare the expression pattern of tumor antigen genes in esophagus carcinoma biopsies and in an allogeneic tumor lysate-based cancer vaccine, MelCancerVac®. Cells used for vaccine production were treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (5-aza-CdR) to determine whether t...

Cancer Immunity (2 April 2009) Vol. 9, p. 3

1Department of Pathology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Warren 827, Boston, MA 02114, USA 2Department of Medicine, Section of Dermatology, University of Chicago, 5841 S. Maryland Avenue, MC 5067, Chicago, IL 60637, USA 3Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, 50 Staniford Street, Suite 200, Boston, MA 02114, U...

Cancer Immunity (19 February 2009) Vol. 9, p. 1

1Medical Oncology, National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany 2Department of Applied Tumor Biology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany 3Hamamatsu Tissue Imaging and Analysis (TIGA) Center, BIOQUANT, University of Heidelberg, Heidelberg, Germany 4Institute of Pathology, University of Heidelberg, Heidelberg, Germany 5Depart...

Cover vol. 9, no.2, June 2012--

Investigation of slice excitation using transmit arrays and non-selective RF pulses

[1] P. Börnert, and T. Schaffter, MRM, vol. 36, no. 6, pp. 932-9, Dec, 1996 [2] T. H. Jochimsen, and D. G. Norris, Magma, vol. 14, no. 1, pp. 50-5, Mar, 2002 [3] U. Katscher, and P. Bornert, NMR Biomed, vol. 19, no. 3, pp. 393-400, May, 2006 [4] P. Ullmann, S. Junge, M. Wick et al., MRM, vol. 54, no. 4, pp. 994-1001, Oct, 2005 [5] Y. Zhu, MRM, vol. 51, no. 4, pp. 775-84, Apr, 2004 [6] M. P. McD...